



A Review on OTIC Preparation Used For Ear and Nasal Cavity.

1VISHVADEEP DAYARAM DESHMUKH, 2SHREYASH VIJAY KOLHE, 3NILESH PRAKASH SONUNE, 4TEJASVI KALYAN EKHANDE, 5POOJA RAM LAMKANE

1STUDENT, 2STUDENT, 3STUDENT, 4STUDENT, 5STUDENT

1SHRI SANT GAJANAN MAHARAJ COLLAGE OF PHARMACY, BULDANA, / SANT GADGE BABA AMRAVATI UNIVERSITY, AMRAVATI, MAHARASHTRA.,

2SHRI SANT GAJANAN MAHARAJ COLLAGE OF PHARMACY, BULDANA, / SANT GADGE BABA AMRAVATI UNIVERSITY, AMRAVATI, MAHARASHTRA.,

3SHRI SANT GAJANAN MAHARAJ COLLAGE OF PHARMACY, BULDANA, / SANT GADGE BABA AMRAVATI UNIVERSITY, AMRAVATI, MAHARASHTRA.,

4SHRI SANT GAJANAN MAHARAJ COLLAGE OF PHARMACY, BULDANA, / SANT GADGE BABA AMRAVATI UNIVERSITY, AMRAVATI, MAHARASHTRA.,

5SHRI SANT GAJANAN MAHARAJ COLLAGE OF PHARMACY, BULDANA, / SANT GADGE BABA AMRAVATI UNIVERSITY, AMRAVATI, MAHARASHTRA.

ABSTRACT: -

Diseases of the observance oppressively impact the quality of life of millions of people, but the treatment of these diseases is an ongoing, but frequently overlooked challenge particularly in terms of expression design and product development. The frequency of observance diseases has prodded significant sweats to develop new remedial agents, but maybe less invention has been applied to new medicine delivery systems to ameliorate the efficacy of observance complaint treatments. This review provides a brief overview of physiology, major conditions, and current curatives used via the otic route of administration. The primary focuses are on the colorful Administration routes and their expression principles. The composition also presents recent advances in otic medicine deliveries as well as implicit limitations. Otic medicine delivery technology will probably evolve in the coming Decade and more effective or specific treatments for observance complaint will arise from the development of lower invasive medicine delivery styles, safe and largely controlled medicine delivery systems, and biotechnology targeting curatives. This review aims to cement three hot motifs in medicine delivery(a) there-formulation of new Products intended for nose- to-brain delivery;(b) the development of nasal casts for studying The efficacy of implicit new nose- to- brain delivery systems at the early of their development(preformulation); the use of 3D printing grounded on a wide variety of accoutrements (transparent, Biocompatible, flexible) furnishing an unknown fabrication tool towards substantiated drug by publishing nasal cast on- demand grounded on CT reviews of cases. This review intends to show the links between these three subjects. Indeed, the pathway named to guide the medicine to the brain not only impact the expression strategies to apply but also the design of the cast, to get the most satisfying measures from it. also, the design of the cast himself influences the choice of the 3D- printing technology, Which, in its turn, bring further constraints to the nasal replica design. Accordingly, the

Formulation of the medicine, the cast medication and its realisation should be allowed of as whole and not independently.

Keyword: - OTIC Ear, Anatomy and physiology of Ear, Determination of Bio adhesive, Nasal Preparation (pre-formulation studies), Intrinsic Properties.

INTRODUCTION: -

According to a WHO check, 250 million People worldwide have moderate to severe hearing loss. The frequency of hearing loss in the USA increases as the population grows and causes serious social and economic burden. Tinnitus, Millions of people worldwide suffer from various hearing disorders and associated conditions similar as otitis media, hearing loss, tinnitus and Meniere's complaint. For illustration, the habitual otitis media or Otitis externa affects 3 – 5% of the US population, with an estimated periodic cost of further than \$ 2.98 billion. Potentially, Life-threatening infections can spread to the middle ear if these conditions are not optimally treated, especially for immunocompromised cases. Meniere's complaint, and autoimmune inner ear disorder complaint are also common diseases that significantly reduce an individual's Quality of life. The frequency of hearing disorders has prompted significant trouble to develop new remedial agents and some trouble has also been directed toward development of ear medicine delivery systems to ameliorate the efficacy of treatments for conditions of the ear. The demand for remedial treatments for hearing disorder complaint is significant, with a request of roughly \$ 10 billion. Still, half of all hearing impairment including deafness may be successfully treated, if fortunately, numerous of these conditions are duly diagnosed and treated in their early stages. The ear is a veritably delicate and anatomically defended organ, and this poses numerous challenges for ear medicine delivery, especially for the treatment of inner ear conditions. Traditional medicine administration routes (e.g., oral routes, injection, and topical routes) have been substantially ineffective for treating inner ear conditions, due to three major physical barriers for medicine delivery to the ear: the tympanic membrane, the round and oval windows (OW), and the blood – perilymph barrier (BPB). Original medicine delivery systems may have significant advantages over systemic medicine delivery systems depending on the complaint and remedial. Original medicine delivery, in utmost cases, maximizes medicine attention in the inner ear while minimizing systemic exposure. Because of this 'pharmacokinetic advantage,' original medicine delivery systems are getting the most common clinical remedy system for the treatment of inner ear conditions. presently, the three main pathways for original medicine delivery to the inner ear are the trans tympanic, intratympanic, and intracochlear routes. Developments in gene and stem cell therapy have also shown that these curatives may be suitable to promote the rejuvenescence of the neural and hair sensitive cells in the inner ear, which give another strategy for the treatment of hearing loss and other hearing disorders. Ear medicine delivery has gained adding interest and has advanced fleetly over the once many decades. Several review papers on ear medicine delivery have been published in the past 10 years, and they've covered the various aspects of ear medicine delivery. Still, extreme of these reexaminations concentrate on only one particular drug delivery strategy or a specific complaint type. Only a really limited number of reexamination papers have directly addressed drug delivery to the ear. also, there is a lack of critical reviews that have epitomized expression design principles of the various original drug administration styles that guide the development of ear drug products. wherefore, this review highlights the introductory expression principles of the various original hearing disorder drug administrations. In this composition, we first give a brief overview of the anatomy and physiology of the ear as it relates to drug delivery. The significant conformity provisions and drug productions are also agitated. The benefits and disbenefits of ear administration routes.

ANATOMY AND PHYSIOLOGY OF THE EAR: -

The middle ear consists of three major corridors: the external ear, the middle ear, and the inner ear. The external ear extends from the auricle, or pinna, along the ear canal and ends at the Tympanic membrane (eardrum). A well-observed ear canal is slightly acidic, with a pH value between 5.0 and 5.7, which can inhibit bacterial growth. At the end of the ear canal lies the tympanic membrane, which separates the middle ear from the external ear. The middle ear includes the ossicular chain, which consists of the malleus, incus, stapes, and a mucosal lining that keeps the middle ear environment moist. The Eustachian tube provides a pathway between the middle ear and the upper airway to allow for equalization of middle ear pressure. The inner ear includes the cochlea, the organs of balance, the Vestibule (utricle and saccule), and the semi-circular canals. The Cochlea is separated into three fluid-filled chambers. The middle cell, called the scala media, is filled with endolymph; while the lower and upper chambers, the scala tympani and Scala vestibuli, are both filled with perilymph. The basilar membrane supports the organ of Corti, which consists of largely arranged mechanosensory cells: the inner and external hair cells (OHC) and their supporting cells (SC). In the auditory process, sound waves are generally collected by the pinna into the ear canal, which causes vibration of the Tympanic membrane. The major function of the tympanic membrane is the transmission of sound waves to the ossicular chain. These vibrations cause the movement of the ossicular chain, and the piston-like stir of the stapes transfers the pressure wave to the inner ear fluids via the round window. The function of the inner ear hair cells converts the auditory information to a bioelectric signal. This signal is also transmitted to the brainstem via the Cochlear Nerve and sometimes to the cerebral cortex, where the information is rephrased into auditory sensations. The first major barrier to drug delivery to the ear is the tympanic membrane,

which is elliptical and slightly conical in shape and separates the middle ear from the external ear. The tympanic membrane is around 0.1 mm thick and consists of three layers: an external epidermal layer, an inner mucosal layer, and a middle fibrous layer with collagen. The tympanic membrane is impermeable to all but fairly small and highly lipophilic molecules due to its keratin and lipid-rich stratum corneum. The tympanic membrane is the first barrier to drug delivery to the middle and inner ear, so it must be traversed if drugs are to be delivered through intratympanic injection or intracochlear injection. Because of its structural similarity to skin, trans-tympanic delivery can transport a drug across a complete tympanic membrane from the ear canal into the middle or inner ear. The alternate major barrier to drug delivery to the ear consists of the round window membrane (RWM) and the round window (OW). These are semipermeable membranes, located at the base of the cochlea, that separate the cochlea from the middle ear. They are viewed either as walls or as paths in terms of drug.

➤ Administration Routes for OTIC Drug Delivery:

Various administration routes have been developed for ear drug delivery. The selection of the administration route depends on the disease and the physicochemical properties of the drug substances. Generally, the administration routes for ear drug delivery can be divided into systemic delivery routes and local drug delivery routes. Systemic drug delivery has multiple limitations, such as the blood-brain barrier and undesired side effects, but systemic drug delivery through oral and intramuscular routes is still considered the most convenient method of drug administration to the various parts of the ear. Oral antibiotics are commonly prescribed for treating acute external otitis and otitis media. However, the disadvantages of oral antibiotics include the possibility of multidrug resistance and imbalance of intestinal flora. Oral steroids, antioxidants, and neuroprotective agents are commonly used to treat sudden sensorineural hearing loss to improve hearing. The other common systemic method is intravenous drug delivery (i.e., intravenous injection), which has been used for severe middle ear infections such as acute mastoiditis and necrotizing otitis externa. Intravenous steroids have also been used to treat hearing loss and Meniere's disease. The side effects of intravenous steroids are similar to those of oral steroids. Some research has shown that steroid nanoparticles can reduce

potential systemic side effects by improving oral bioavailability. Local drug delivery During the past decade, interest in local drug delivery for the therapy of ear diseases, especially for the inner ear, has increased significantly. Compared to systemic administration, local application Has many advantages, especially for drugs that have a narrow Therapeutic window, significant first-pass metabolism, or serious side effects. The advantages of local drug delivery are the ability to bypass the BPB, higher local drug concentration, and (3) Reduced side effects. Four types of local delivery systems are currently in use: topical, trans tympanic, intratympanic, and cochlear delivery. Topical drug delivery Topical drug delivery has long played an important role in treating Ear disorders. This route involves direct administration of a drug into the ear canal. Commonly used topical medications include Topical antibiotic, and antifungal drugs in the form of drops, Gels, or foams. Intratympanic drug administration the middle ear has been used as a reservoir for drugs that can then diffuse through the round window into the inner ear. Intratympanic drug delivery involves injecting the drug in the middle ear cavity.




Figure 1: Anatomy of Ear

➤ Recent Advances in OTIC Drug Delivery:

Significant advances in otic medicine delivery have been achieved in the once decade. In the once many times, several patents have been Filed on new composites and medicine delivery systems for the treatment of inner observance conditions. An advanced understanding of the mechanisms of inner observance conditions has led to new medicines that Target the voltage-gated potassium ion channels, glutamate receptors, and impediments of the notch experimental signalling pathway in order to treat hail loss, tinnitus, and supplemental vestibular Dysfunction. The development of sustained medicine delivery to the RWM is also pivotal for original delivery to the inner observance. El Kechai et al. estimated a hyaluronic acid liposomal gel for the sustained delivery of A corticoid to the inner observance after original injection into the middle observance in a guinea gormandizer model. Dragged hearthstone time at the point of Injection, as well as in the round window, was achieved without Negative effect on the hail thresholds of the beast. The presence of liposomes in the expression redounded in sustained medicine Release in the perilymph for 30 d. Yu et al. developed an injectable cut Silk hydrogel to chieve Sustained release of glucocorticoid. The glucocorticoid attention in the perilymph remained below 100 mg/ mL for at least 10 d for the PEG- Silk expression, but lower than 12 h for the control for Emulation of free glucocorticoid. The advancement of new polymer accoutrements and nanoparticle curatives also give indispensable strategies to ameliorate medicine saturation through the inner observance walls and target particular cells in the inner observance. Yoon et al. developed Arg8- conjugated Nanoparticles as a controlled medicine release system for inner observance remedy. The study results show that the nanoparticle is a promising seeker for medicine or gene delivery. It has been reported That the objectification of nanoparticle systems into a hydrogel Increases the hearthstone time of the nanocarrier in the

middle observance, therefore enhancing medicine attention in the inner observance. Lajud et al. have developed a nanohydrogel in which the Liposome was incorporated into a chitosan hydrogel. They discovered that the nanohydrogel releases the liposome in a controlled and sustained manner, and their in vivo study demonstrated that Intact liposomes were delivered into the peri lymphatic space and reached cellular structures in the scale media. An adding number of new chemical realities are in the preclinical or clinical stage. summarizes the product channel for original otic medicine delivery. numerous of these composites have demonstrated promising results for treating inner observance diseases in an Effective and targeted manner. Significant advances in Characterizing the medicine release study in the inner observance will promote the development of inner observance medicine delivery.



Figure 2: Nasal Drop

➤ **Current challenges in otic drug delivery:**

Although significant advances in otic medicine delivery were achieved in the last decade, numerous challenges have yet to be overcome. The Difficulties are substantially related to the biology of the observance and the Molecular mechanisms of the inner observance conditions. The pathology of some of inner observance conditions is inadequately understood, including sensorineural hair loss, Meniere's complaint, and tinnitus. Our limited knowledge of these inner observance conditions Makes it grueling to find an effective medicine and delivery strategy. With a better understanding of the deconstruction of the inner observance and the pathology of inner observance conditions, further effective otic medicine Products will be available on the request. In addition, the pharmacokinetics of medicines in the inner observance are Not well defined, and data are limited regarding medicine distribution, round window permeability, and original bioavailability in the inner observance. There are no standard testing styles for assessing inner observance medicine delivery. For illustration, Franz proximity cells are Generally used to estimate transdermal and topical medicine delivery phrasings. still, this system, as well as the use of other Being in vitro proximity cell systems, may not be suitable to estimate medicine proximity through the middle observance and the RWM. An Accessible and effective in vitro proximity cell system for assessing intratympanic phrasings for inner observance medicine delivery is n't yet available. likewise, because the fluid volume in the inner observance is Extremely small, it's delicate to give acceptable samples for analysis by conventional logical styles. largely sensitive ways, similar as LC- MS, are more acclimated for assays in perilymph Samples, but the fashion is complex and precious. dimension of medicine attention at different locales in the cochlea presents a specialized challenge for studying the perilymph Pharmacokinetics. Although original medicine delivery to the inner observance has been extensively Accepted in clinical practice, the choice of medicines and operation Protocols in human is largely empirically deduced. Study of the pharmacokinetics of medicines in inner observance will come decreasingly important for optimization of clinical practice and the development of otic medicines. There are significant obstacles to study the pharmacokinetics of medicines in inner observance. The pharmacokinetic Properties deduced from beast trials might not represent Those in humans. Pharmacokinetic is also affected by the inner observance conditions. The computer simulation software developed by Salt has Demonstrated significant pledge in easing the understanding of medicine pharmacokinetic in the inner observance. To date, the cochlear fluids simulator software is one of the most comprehensive simulation programs of the observance. It can be

used to calculate the effective medicine attention achieved when medicine is delivered directly to the inner observance of guinea gormandizer, mouse, and mortal. The Simulation medium is grounded on the fine computation of physical process, which involves solute disbandment through prolixity, Longitudinal fluid inflow, and concurrences to other chambers. This approach has been validated in multitudinous trials in Which ion- picky electrodes were used to quantify the spread of Marker substances in the cochlear fluids. Experimenters have employed both in vitro and in vivo styles to probe otic medicine delivery systems, but the in vitro – in vivo Correlation study is overlooked, and many reports compare the in Vitro and in vivo styles.

❖ DETERMINATION OF BIOADHESIVE PROPERTIES: -

Bio adhesion provides a surrogate measure for the roof time of the otic products at the point of operation and eventually determines the extent of medicine immersion. Bio adhesion was estimated using the TA. XT Plus Texture analyser (Stable Micro Systems). To texture analyser setting used to test the stickiness of tenacious slush was used in this study. Rat skin (subject to collection blessing by way of institutional scavenged kerchief announcement) was used as a bio adhesive face. It was attached to a spherical inquiry with a rubber band and 0.2 g of the sample product was placed in the canter of a weigh boat which was fixed to the base of the texture analyser with tenacious putty. The inquiry, with skin attached, was lowered at a constant speed of 0.5 mm/ sec into the sample product. To communicate time was 3 s and a constant downcast force of 500 g before rising to the return distance of 10 mm at a constant speed of 1.0 mm/ sec. To detachment force recorded by the Exponent software was used to determine and compare the differences in bio adhesive parcels of marketable COE products. For each product tested, the rat skin was replaced with a virgin Piece. The test was performed in trio.

1. Droplet size Determination

An importing scale was used to estimate the drop size. Ten drops attained directly from each otic product as packed were collectively measured for each product. The average drop weight and standard divagation were calculated. The drop mass is assumed to be commensurable to drop size. Result and discussion pH value to normal canine skin pH ranges from 5.5 – 7.2, slightly more alkaline compared to the pH of mortal skin which is in the range of 4 – 6(20 – 22) and analogous to the pH of the epithelium of the EAC of tykes with normal cognizance (4.6 – 7.2). In the EAC of tykes with habitual COE, the pH Tends to have a advanced range of (6 – 7.4), whilst in acute COE the pH tends to be on the lower side ranging from 5.2 to 7.2. From the range of marketable products, we've named from the study, only Baytril Otic is waterless- grounded with an approximate pH of 6.26 ± 0.04 . This is an ideal property as it's analogous to the pH range of a healthy canine's EAC, hence it's less likely to disrupt the micro-environment needed for the conservation of healthy skin. likewise, the EAC is well softened and the impact of any administered product is likely to be flash.

2. Viscosity Evaluation

Density is a vital property of pharmaceutical medications and it's generally modified by expression scientists to control the retention times of topical medicines at the point of operation. the density of the estimated products varied significantly. utmost of the products had a density in the range of 0 – 1 PA's. Osumnia displayed the loftiest density at 4 °C (15.5 PA's), 5 times lesser than Surolan (2.8 PA's). The density of Osumnia was temperature-dependent and was significantly reduced at 39 °C, this can affect in reduced retention time in an infected EAC. the high density of Osumnia could be related to the polymer, hydroxypropyl methylcellulose (HPMC) present in the expression. Baytril Otic and Demotic demonstrated the smallest density values at both temperatures. Compared to the other products in the study, shear rates and RPM were larger, while necklace was lower, indicating a low quantum of shear.

3. Bioadhesion Evaluation

Bio adhesion studies were conducted to study the retention time of the products at the point of operation. Among the estimated marketable products, the product osumnia had the loftiest detachment force (124.3 g), a marker of bio adhesive strength. The bio tenacious strength of Osumnia could be attributed to its gel expression

and the high density of the polymer used, HPMC. HPMC is known to have strong bio tenacious property which is not told by pH. The hydrophilic nature of HPMC contributes to advanced lump of the polymer and thus a advanced extent of memoir adhesion. In discrepancy, Baytril otic and Aurizon observance drops displayed low detachment force (14.6 g and 17.4 g, independently) indicating poor bio adhesive parcels. This is probably due to the expression of the products as both Baytril Otic and Aurizon observance drops are not gel- grounded and do not incorporate polymers within their expression. phrasings with good bio tenacious parcels will demonstrate better retention time on the infected area of the EAC, allowing the drug to be delivered efficiently which directly improves the efficacy of the product. Several factors delved in this study so far feel to impact the memoir cohesion of otic phrasings similar as the type of polymer used, pH, and temperature.

4. Spreadability Evaluation

A topical expression with good spread ability parcels facilitates indeed operation of the product to the skin optimising medicine delivery. The spread capability of the otic drops shows an inverse relationship to density. These marvels are verified in the findings of our Study, for illustration, Osumnia a product with high density demonstrated the smallest spread ability with an average value of 35 mm. While products with poor spread ability have good retention parcels, poor spread ability can affect the ease of operation. Hence the density of the product has to be finely balanced to accommodate for applicable spread capability and product retention.

5. Syringeability Evaluation

Studies have reported the difficulty of achieving harmonious dosing using the personal holders, hype administration has been suggested to grease the delivery of an applicable quantum of some products. The hype capability of a topical product is an important factor that requires consideration during expression development. Hype capability measures the force needed to expel the product from a hype. The hype capability force can serve as a surrogate for the force needed to administer the product from its vessel. The lower the force needed to expel the product, the better the hype capability. Results from hype capability studies are largely determined by the rheological geste of each product. A product flaunting shear thinning geste will present lesser Syringe capability than other inflow behaviours. Baytril Otic had the smallest hype capability force (137 g) followed by Osumnia (141 g). The small hype capability force needed for these products suggests they've good many parcels enabling easier administration of the otic product from the personal vessel.

❖ NASAL PREPARATION: -

Over the once many times, nose- to- brain(N2B) delivery has entered growing interest. This system of administration is grounded on medicine delivery in the nostrils to target the central nervous system. To reach the brain, the medicine must reach the olfactory zone which are located at the top of the nasal depressions. also, it must diffuse through the nasal mucosa and the olfactory jitters towards the brain. The main advantage of this N2B administration is its capability to bypass the systemic rotation. thus, it avoids implicit enzymatic declensions due to hepatic first- pass and allows bypassing the blood- brain hedge. also, it allows dwindling the remedial cure and the posterior side goods. This way of delivery is intriguing in the treatment of severe brain pathologies similar as tumours or the treatment of degenerative neuronal complaint similar as Parkinson's and Alzheimer conditions. Principle of nose- to- brain delivery (1) medicine expression;(2) instillation;(3) Transport in the depressions and impaction of the mucosa (4) transport in the olfactory mucosa Adhesion, dissolution, mucociliary concurrence and prolixity;(5) transport through the epithelium and along the olfactory whim-whams. Source images by Servicer Medical Art. However, the N2B delivery of a medicine is known to be grueling. Indeed, the instillation of the medicine into the nasal depressions must lead to the deposit of a significant bit of the inseminated cure in the olfactory zone. It's far from being egregious, due to the complex figure of these depressions, the olfactory region being in their upper part. Another option is to use the trigeminal whim-whams to get direct access to the brain. The main advantage of using this alternate route is that the trigeminal whim-whams spans over the whole nasal depression and so the targeting is easier. In both cases, while the medicine diffuses through the nasal mucosa, the expression must help any implicit

early declination by enzymes and its concurrence by the natural beating of the cilia lining the epithelium of the nasal depression. Rigorous pre-formulation studies should be performed to face these challenges and succeed in the further development of an effective N2B expression. In pre-formulation studies, the physicochemical parcels of a medicine seeker and its comity with excipients are characterized. The thing of these studies is to increase the solubility and bioavailability of the medicine. Pre-formulation studies also ensure good case compliance to the treatment by opting the right osmolarity (200- 600 mothers' l) and pH (5-6.5) (1 – 3,19), perfecting the stability of the final product and guaranteeing an absence of toxin. In N2B Delivery, pre-formulation studies also aim at generating patches with a mean periphery similar that a minimal bit of the inseminated cure can reach the brain. similar aerodynamic mean periphery is known to be dependent on the type of instillation device and the inflow generated in the nasal depressions. In addition to the pre-formulation studies, 3D- published clones of nasal depressions (so- called “nasal casts”) are precious tools. They allow making a link between the parcels of a expression seeker, the parameters of an administration device and the transport in the nasal depressions. thus, they can be used to ensure applicable targeting of the olfactory zone, which is a central element for the success of N2B remedy. similar clones should be 3D- published with a material that is not pervious and does not intrude with the quantification of a medicine seeker during pre-formulation studies, as well as in quality control analysis. also, the 3D printer should have a smooth face and a sufficient resolution. Next to “standard” nasal casts, casts may also be carpeted with artificial mucus to mimic the eventuality in vivo geste of the impacting patches in an in- vitro device. This review aims to give a clear and global overview of the current knowledge and open questions regarding N2B delivery (Figure 2). There are three main stages pre-formulation studies, device selection and tests in 3D- published nasal casts. The pre-formulation studies section focuses on the physio- chemical parcels of the medicine. It also illustrates the significance of pre-formulation studies to ameliorate the mores of API and shows the final strategies to enhance the bioavailability of the expression. The section devoted to the description of the bias describes the different instillations that are presently used and their influence on the success of the N2B treatments. The 3D- published nasal cast section describes the significance of designing the nasal casts following the constraints linked to the compass of the study. also, it compares the different 3D printing ways used for nasal replica product. Eventually, it underlines the part of mucus in flyspeck prisoner by the walls. Due to the failure of available data, this paper does not concentrate on in- vivo studies and neither on the correlation between in- vitro and in- vivo data.

➤ **Pre-formulation studies: -**

This section describes the different way to reach a safe, stable and effective expression. Indeed, treatments should be durable in time, safe for the case and yield the applicable remedial cure. The first step consists of relating the physiochemical mores medicine candidates. partition measure, pKa, molecular weight) as they can impact their solubilisation in mucus or their saturation through the olfactory epithelium. To estimate pre-formulation characteristics, there are three crucial targets expression stability, Nasal mucosa preservation and treatment effectiveness. This part illustrates the significance of pre-formulation studies to ameliorate N2B- medicine parcels. Eventually, this section exposes the approaches used to ameliorate the bioavailability of expression for N2B delivery. The strategy focuses on adding medicine bioavailability and dwindling mucociliary concurrence and enzymatic declination. A summary of the pre-formulation studies workflow is described. The active component is first characterised in terms of acidic dissociation constant (pKa), partition measure (log P) and molecular weight (Mw). also, pre-formulations studies aim to produce a stable, safe and effective expression. fresh strategies (saturation enhancers, colourful pharmaceutical forms, nanocarriers) can be used to ameliorate medicine bioavailability. Applicable physiochemical mores of a medicine regarding its N2B delivery several physiochemical mores of a medicine intended for N2B delivery should.




Figure3: 3D Image of Nose

➤ **Solubility and absorption: -**

Solubility is the maximum volume of a substance that can fully dissolve in a unit volume of detergent. The medicine solubility is one of the essential factors to consider in pre-formulation studies since the medicine must be dissolved to a large extent to diffuse through the mucosa and, also, through the olfactory region (i.e., through the olfactory jitters located in the cribriform plate). also, N2B delivery involves the rapid-fire dissolution of the inseminated medicine in a small liquid volume (between 50 and 150 μL). Indeed, medicines must be dissolved to be absorbed. The typical cure for a N2B medicine is in the order of 20 μg . So, their solubility should be at least 0.2 g/ l to fully dissolve in the mucus subcaste and also be absorbed. Several pre-formulation evaluations may be performed to estimate the solubility of medicines in detergents, waterless buffers or canvases. The shake beaker system and the test tube system enable determining this solubility. The solubility of an ionic medicine correlates with its Partition measure and its pKa. after intranasal administration, the medicines must be absorbed through the olfactory epithelium to reach the brain. The factors impacting the dissolution of the active component (Hydrophilicity, pKa, Molecular weight) also control its immersion. So, the original phase of pre-formulation studies should study these two aspects at formerly.

❖ **INTRINSIC PROPERTIES: -**

a. Partition coefficient

The partition measure of a medicine describes its hydrophilic/ lipophilic geste that influences both its solubility and its prolixity through the epithelium. Indeed, the advanced the lipophilicity of the medicine is, the easier it travels across epithelial cells. The octanol/ water partition measure ($\log P$) describes medicine hydrophobicity. The partition measure is the logarithm of the rate of attention at equilibrium $\log P = \log \frac{C_{\text{octanol}}}{C_{\text{water}}}$ (1) therefore, a lipophilic medicine has a $\log P > 0$, and a hydrophilic medicine has a $\log P < 0$. The larger this $\log P$ is, the further the medicines are lipophilic. The hydrophilic medicines route is called the paracellular route. There's an inverse relationship between the molecular weight of the hydrophilic medicine and its capability to diffuse between cells (1 – 3). In N2B delivery, the transcellular route is the top route for medicines immersion. therefore, lipophilic medicines are more absorbed than hydrophilic motes. The hydrophilic medicines have low permeability across the olfactory epithelium. The C_{max} in brain after intranasal administration of their nanoparticle expression compared with the medicine result is 7 times advanced ($3.44 \pm 0.03 \mu\text{g/ mL}$ and $0.48 \pm 0.04 \mu\text{g/ mL}$ independently).

b. pKa

The pKa is the pH at which the acid dissociates. This dissociation correlates with the solubilisation of the ionizable drugs and thus their absorption. The proportion of ionized drugs depends on the nasal pH, usually range between 5.0 and 6.5 [1–3,19] and on its pKa. The Henderson-Hasselbach equation illustrates this relation: $\text{pH} = \text{pKa} + \log \frac{[B^-]}{[A^+]}$ (2) Equation 2 shows that if the drug pKa is lower than the pH of the formulation, the base form dominates. In contrast, if the pKa of the drug is higher than the pH of the formulation, the acid form dominates. For base drugs, the base form has no charge and the conjugate acid is

cationic, while for acidic drugs, the acid form is neutral and the conjugated base is negatively charged. For instance, levodopa is an anti-Parkinson acidic drug with pKa equal to 2.32. So, in the conditions described above, it will be mostly ionized. Risperidone is a basic drug with pKa equal to 8.76. Therefore, in nasal conditions, it will also be mostly ionized. The lipophilic drugs have a poor dissolution rate in a small volume of nasal liquid. Thus, on their charged form, their solubility and their absorption increase. Moreover, the cationic substances interact with negatively charged mucins of the nasal mucosa, which increase their affinity and remanence. On the other hand, the hydrophilic drugs have a suitable dissolution rate. However, the absorption in olfactory epithelium is better on their neutral form, [1,3,36]. shows a summary of dissolution and absorption of drugs as a function of their hydrophilicity and lipophilicity. As most acidic drugs have a low pKa and basic drugs have a high pKa, the most suitable drugs are lipophilic basic drugs (unionised if their pKa is lower than 5) and hydrophilic basic drugs.

c. Molecular weight

The medicine immersion directly correlates with the molecular weight (Mw). Indeed, a medicine with MW advanced than 1000 Da is generally characterized by poor immersion (1 -). For lipophilic medicines, API with a Mw lower than 300 Da generally diffuse through unresistant prolixity. on the other hand, carrier-intermediated transport is known to be used by notes with a Mw ranged between 300 and 1000 Da. For hydrophilic medicines, the immersion is directly commensurate to the Mw. therefore, their immersion rate proportionally decreases when the Mw is advanced than 300 Daae strategy to ameliorate the bioavailability of macromolecular medicines (further than 1000 Da) in N2B delivery is the use of cell- piercing peptide (CPP). Lin et al. explained the bettered brain penetration of their CPP- protein nasal expression by the micropinocytosis. Indeed, this CPP capacity allowed the medicine to resettle deeply by drenching the cell layers one by one and so explained the medicine prolixity by transcellular pathway). Yan et al. compared the brain effectiveness of their nanoparticles and their nanoparticles conjugated with CPP. They demonstrated a chance 6 times advanced for the CPP in olfactory bulb (0.405 vs 2.64) and 3 times advanced for the CPP in mind (0.95 vs 3.36) (47Pre- expression describes both physicochemical parcels and kinetic rate profile of a new medicine (i.e., its outgrowth in the organism). It also evaluates the comity between medicines and excipients as well as the processability of the medicine. This strategy increases the impactation of the expression onto the olfactive region as well as the prolixity of the medicine through the neuroepithelium. To this end, it's pivotal to assess the comity between the medicine and the excipients. also, Experimenters should also estimate the implicit toxin of the final expression. also, pe-Formulation also aims to ameliorate the stability of a developed expression through product and long- term storehouse.

d. Stability during storage

The nasal expression must insure the stability of the medicine over time during storehouse. It also covers the physical and chemical stability of the set conflation, dormancies or results (in the case of liquid expression). This stability may be attained using several strategies. For liquid phrasings, it can be advised to add antioxidant (e.g., oxidizable API/ excipients) and antimicrobial agents. But this kind of substances may be irritant or allergenic for the patient Demonstrated the significance of the choice of antioxidants in liquid phrasings. Indeed, they studied the antioxidant exertion of different antioxidants for levodopa. Their pre-formulation studies allowed them to elect the stylish antioxidant in low attention. It's possible to avoid the use of similar preservatives with the development of dry phrasings. Those phrasings were formerly described to increase the stability of vaccines. Another point to estimate is the implicit declination of the inseminated medicine by the enzymes present in the intranasal depression. For case, these enzymes are carboxylesterase, aldehyde dehydrogenases or cytochrome P450. The final point to bandy is the colloidal stability of dispersed systems. Colloidal stability may be estimated by measuring the zeta eventuality of the expression. A zeta eventuality above 20 mV or below -20 mV indicates that the colloidal system is stable. Other means to describe colloidal systems stability are the patches size distribution and the polydispersity indicator (PDI). Indeed, the polydispersity indicator is a measure of the diversity of a sample grounded on its size distribution. Indeed, a colloidal system has a narrow flyspeck size distribution with PDI values ranged between 0.1- 0.2. Stability

can be increased with the use of a steric stabilizer. Shubin et al. illustrated the significance of pre-formulation to ameliorate colloidal stability.

e. PH

As explained preliminarily, the pH of the expression influence medicines ionization and stability. Olivier et al. impeccably illustrated this point. Indeed, they studied the pH of nasal expression influence in midazolam immersion. They demonstrated an effective immersion in pH 5.5 and 7.4 compared with pH 3.3. Indeed, the chance of unionized form is 20 and 95 in pH 5.5 and 7.4 independently. In the smallest pH values, the proportion of unionized form is poor and therefore the immersion decreases. permitted pH range for nasal phrasings. But piecemeal from the influence on the API, the pharmaceutical forms must admire a range of ph. In fact, for intranasal administration, the pH of the liquid form or the greasepaint form after dissolution must be between 4.5 and 6.5 to be well permitted.

f. Toxicity

The FDA's website provides an Inactive Ingredients Database that contains a list of excipients that may be used according to the administration route and the tolerated dose. Moreover, histological evaluations allow the evaluation of ciliotoxicity or mucosal toxicity. Wang et al. studied the nasal ciliotoxicity of retigabine-loaded polymeric micelles in thermosensitive hydrogels. They evaluated the duration of cilia movement after formulation exposition and the inflammatory state of the tissue. No significant modification of the cilia movement duration was observed between the control solution and the drug-loaded formulation: respectively 599 ± 16 min and 554 ± 25 min. And for the nasal tissue integrity, they measured that the duration of the cilia movement after formulation application was 92.5% of the duration before application. They considered that the drug and its excipients had no apparent damage to the cilia movement. Therefore, these pre-formulation studies confirmed the safety of their formulation before the in-vivo studies. another preclinical analysis evaluated the toxicity of the pre-formulation is to evaluate cell viability [55,73,82,84]. Kim et al. used the MTT assay to assess the toxicity of their formulation. Indeed, the use of permeation enhancers may lead to higher bioavailability of drugs. However, their potential toxicity to the mucosal site after repeated administration restricts their further applications. Thus, they proved a low reduction of relative cell viability after 24h contact between their formulation and the RPMI2650 cell line (more than 70% of cell viability). This kind of pre-formulation study should be used to choose the safest excipient for N2B formulation. Kim et al. also used a more specifically pre-formulation analysis for N2B delivery. They made primary neuronal cell culture with rats. In vitro optical microscopy was performed to observe the effect of their formulation on the morphology of primary neurons to validate the safety of the formulation.

g. Viscosity

The viscosity of the expression greatly contributes to adding drug absorption. viscosity has two goods on absorption. A properly named viscosity decreases the mucociliary concurrence (MCC) and increases the roof time as well as the absorption of drugs. In distinction, devilish viscosity may drop drug diffusion through the expression and the olfactory region (37,85). Stokes- Einstein equation illustrates this phenomenon $D = \frac{kT}{6\pi\eta a}$ (3) Where D = diffusion measure; k = Boltzmann constant; T = absolute temperature; η = viscosity of the medium/ soap; a = molecular compass. According to equation 3, the further the viscosity increases, the further the diffusion measure decreases. This point illustrates the significance of a pre- expression study because researchers must develop a sufficiently thick expression to drop the MCC but not too important to gain an effective release of API. Furubayashi et al. studied the effect of viscosity phrasings between 1.2 and 147.11 scars) in nasal absorption and MCC in rats. They vindicated that an increase in the viscosity increases the mean resistance time of the expression in rat nasal depressions. But for the mostthick expression (147.11 mass), the nasal absorption decreases approximatively by 30 in comparison to the control expression. Pires et al. For liquid phrasings, the alternate important part is the influence of viscosity in the device. indeed, viscosity modifies the decoration angle and the targeting parcels of the expression. Pu et al. added microcrystalline cellulose (Avicel) or hydroxypropyl methylcellulose (HPMC) to arid mometasone furoate results to reach

viscosity from 1.3 to 21.8 pct. Adding 2 w/ w of Avicel ® in result increased the viscosity by a factor of 17 While the decoration angle lowered from 50 ° to 46 °. also, adding 0.3 w/ w of HPMC made the decoration angle drop by 12 ° while multiplying the viscosity by 6. Also, Warnke net al. added HPMC in cromolyn sodium nasal result to increase the viscosity from 1 to 53.1 pct. At the same time, the decoration angle dropped from 48 ° to 24 °.

h. Particle size distribution

The flyspeck size distribution is another important parameter to estimate when the administration aims to target the olfactory region. For dry maquillages, several studies concluded that a mean periphery around 10 µm maximises the quantum of greasepaint that could impact the olfactory zone. In a recent paper, Yarlagadda et al. studied the deposit effectiveness in the olfactory region. They compared two different models of bias nebulizer, propelling the patches in a single nostril, and bi-directional tailwind, creating a circulating tailwind across the two sides of the nose. They concluded that the ideal mean periphery should be ranged from 8 to 12 µm. also, Schroeter et al. set up that 10 µm patches are the most effective mean periphery to reach the olfactory zone. It underlines the significance of a pre-formulation step taking into account flyspeck size to gain patches acclimated for nose- to- brain delivery. For the N2B delivery, liquid phrasings feel to be less effective than the dried systems. Calmat et al. studied, via computer simulations, the nasal deposit in the olfactory region of nasal scattered patches under different simulated alleviations. They demonstrated the same conclusions as former studies the use of a liquid expression for N2B delivery is hamstrung. Other brigades also concluded an ineffective deposit on the upper turbinate region with a nasal liquid spray Warnken et al. observed a maximum olfactory bit of 2.2 of the emitted cure, and Shah et al. find only about 0.4 of the emitted medicine in the olfactory region. Kailee et al. concluded the same inefficiency, but they demonstrated a minimal deposit effectiveness in everyday- life operation conditions in the turbinate for flyspeck size ranging between 20- 30 µm). It worth noting that liquid expression still provides rather good results in creatures. still, these studies do n't calculate on a spray to guide the expression but directly wash the depressions. Accordingly, flyspeck size produced while delivered to a human doesn't play any part there.

i. Pharmaceutical forms

The main advantages and disadvantages of these different forms are illustrated in. As already mentioned, it has been demonstrated that dried powder formulations have more advantages than liquid formulations. The pre-formulation studies could demonstrate the advantages of pharmaceutical form in terms of bioavailability. Indeed, Fransen et al. demonstrated that dry powder formulations exhibited a greater bioavailability than nasal liquid formulations. The Cmax of intranasal liquid and powder spray are respectively 34.1 and 103.3 pg./m. This fact has been confirmed by patients, who declared that the powder did not run down the throat. Also, the nasal dry powder formulations contained starch as permeation enhancers. The starch can increase paracellular absorption of the drugs by opening thigh junctions. Moreover, Vasa et al. demonstrated the importance of powder granulometry on nasal dry powder cohesion. Indeed, the micronation of nasal dry powder allowed to rapidly reaching the saturated concentration of drugs on the nasal epithelium surface. That explained the higher permeation through the membrane for dry formulations compared to liquid formulations. For this pre-formulation study, they selected microparticles with a particles size of lower than 20 µm. Indeed, olfactory deposition is optimum in the range of 8-12 µm. Another relevant advantage of powder drug-loaded formulation is its higher stability, which makes them a relevant candidate in vaccines development. The main advantage of them in comparison with liquid forms is their capacity to increase the residence time on the nasal epithelium and increase the drug bioavailability. This advantage comes from their higher viscosity and their ability to swell upon contact with biological fluids. Moreover, their administration.

Conclusion: -

This review highlighted the importance of pre-formulation in the development of new nose-to-brain drugs. In vivo tests proved that a good optimization beforehand leads to better bioavailability. Indeed, cautious pre-formulation can increase the residence time, decrease the mucociliary clearance and strengthen the permeation through the mucosa. For testing the obtained formulations more realistically than in vivo tests on mice, 3D-printed nasal casts represent a great interest. Moreover, they can be adapted for each patient. So, it allows health professionals to create personalised administration protocols, maximising the amount of drug reaching the brain. Better nasal replicas would also lead to a better understanding of the key parameters to further improve drug deposition on interest sites. This could lead to better design of instillation devices or even new concepts of administration. Better pieces of equipment could also provide clues for tailor-made formulations and for adjusting the existing strategies. However, their design should incorporate the study objectives to ensure an in vitro – in vivo correlation. To date, only a few teams studied in vitro – in vivo correlations. While some results are encouraging, others show that imprecision in cast conception can lead to no correlation. In vivo is where most of the work is still needed. First, the properties of the formulation have been extensively tested on mice but not on humans. Therefore, clinical trials should be done to ensure that they are also valuable for patients.

REFERENCE: -

- [1] Osguthorpe JD, Nielsen DR. Otitis externa: review and clinical update. *Am Fam Physician*. 2006; 74:1510–1516.
- [2] Shebelle PG, Takata G, Newberry SJ, et al. Management of acute otitis media: update. *Evid Rep Techno Assess (Full Rep)*. 2010; 198:1–426.
- [3] Coco AS. Cost-effectiveness analysis of treatment options for acute otitis media. *Ann Fam Med*. 2007; 5:29–38.
- [4] Viol MM, Holme RH. Hearing loss and tinnitus: 250 million people and a US\$10 billion potential market. *Drug Discov today*. 2005; 10:1263–1265.
- [5] Lin FR, Niparko JK, Fiorucci L. Hearing loss prevalence in the United States. *Arch Intern Med*. 2011; 171:1851–1853.
- [6] Syed I, Aldren C. Meniere's disease: an evidence-based approach to assessment and management. *Int J Clin Pract*. 2012; 66:166–170.
- [7] Meyer T. Intratympanic treatment for tinnitus: a review. *noise Health*. 2013; 15:83–90.
- [8] Ruckenstein MJ. Autoimmune inner ear disease. *Curr Opin otolaryngol Head Neck Surg*. 2004; 12:426–430.
- [9] WHO.int [Internet]. New York: World Health Organization;2018. Prevention of blindness and deafness. Available From: <http://www.who.int/pbd/deafness/facts/en/>.
- [10] Esterberg R, Coffin AB, Ou H, et al. Fish in a dish: drug discovery for hearing habilitation. *Drug Discov Today*.2013;10: e23–e29.
- [11] Liu H, Hao J, Li KS. Current strategies for drug delivery to the inner ear. *Acta Pharmaceutica Sinica B*. 2013; 3:86–96.
- [12] Valente F, Astolfi L, Simoni E, et al. Nanoparticle drug delivery systems for inner ear therapy: an overview. *J Drug Deliv Sci Technol*. 2017; 39:28–35.

- [13] V. Pandey, A. Gadeval, S. Asati, P. Jain, N. Jain, R.K. Roy, M. Tekade, V. Soni, R.K. tekade, Formulation strategies for nose-to-brain delivery of therapeutic molecules, elsevier Inc., 2019. <https://doi.org/10.1016/B978-0-12-814487-9.00007-7>.
- [14] N.R. Hussein, H.K. Omer, A.M.A. Elhissi, W. Ahmed, Advances in nasal drug delivery systems, Elsevier Inc., 2020. <https://doi.org/10.1016/b978-0-12-819712-7.00015-2>.
- [15] S. Moinuddin, S. Hasan Razvi, M. Fazil, M. Mustaneer Akmal, C. Syed Moinuddin, M. Shahnawaz Uddin, S. Shahidullah, Nasal drug delivery system: A innovative approach, ~ 169 ~ Pharma Innov. J. 8 (2019) 169–177. www.thepharmajournal.com.
- [16] F. Sabir, R. Ismail, I. Csoka, Nose-to-brain delivery of anti glioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook, Drug Discov. Today. 25 (2020) 185–194. <https://doi.org/10.1016/j.drudis.2019.10.005>.
- [17] P.G. Upadhaya, S. Pulakkat, V.B. Patravale, Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management, Drug Deliv. Transl. Res. 10 (2020) 1044–1056. <https://doi.org/10.1007/s13346-020-00747-y>.
- [18] A.D. Kulkarni, Y.H. Vanjari, K.H. Sancheti, V.S. Belgamwar, S.J. Surana, C. V. pardeshi, Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: A mini review, J. Drug Target. 23 (2015) 775–788. <https://doi.org/10.3109/1061186X.2015.1020809>.
- [19] M. Agrawal, S. Saraf, S. Saraf, S.G. Antimisari, M.B. Chougule, S.A. Shovel, A. alexander, Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs, J. Control. Release. 281 (2018) 139–177. <https://doi.org/10.1016/j.jconrel.2018.05.011>.
- [20] A. Alexander, S. Saraf, Nose-to-brain drug delivery approach: A key to easily accessing the brain for the treatment of Alzheimer's disease, Neural Regen. Res. 13 (2018) 2102–2104. <https://doi.org/10.4103/1673-5374.241458>.

